8-21976387-A-G
Position:
Variant summary
Our verdict is Likely benign. Variant got -5 ACMG points: 1P and 6B. PP2BP4_ModerateBS2
The NM_015024.5(XPO7):āc.629A>Gā(p.Glu210Gly) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000479 in 1,461,630 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ).
Frequency
Genomes: not found (cov: 32)
Exomes š: 0.0000048 ( 0 hom. )
Consequence
XPO7
NM_015024.5 missense
NM_015024.5 missense
Scores
1
8
10
Clinical Significance
Conservation
PhyloP100: 7.54
Genes affected
XPO7 (HGNC:14108): (exportin 7) The transport of protein and large RNAs through the nuclear pore complexes (NPC) is an energy-dependent and regulated process. The import of proteins with a nuclear localization signal (NLS) is accomplished by recognition of one or more clusters of basic amino acids by the importin-alpha/beta complex; see MIM 600685 and MIM 602738. The small GTPase RAN (MIM 601179) plays a key role in NLS-dependent protein import. RAN-binding protein-16 is a member of the importin-beta superfamily of nuclear transport receptors.[supplied by OMIM, Jul 2002]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -5 ACMG points.
PP2
Missense variant in gene, where missense usually causes diseases (based on misZ statistic), XPO7. . Gene score misZ 4.8157 (greater than the threshold 3.09). Trascript score misZ 5.4671 (greater than threshold 3.09). GenCC has associacion of gene with prostate cancer.
BP4
Computational evidence support a benign effect (MetaRNN=0.18427587).
BS2
High AC in GnomAdExome4 at 7 AD gene.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
XPO7 | NM_015024.5 | c.629A>G | p.Glu210Gly | missense_variant | 7/28 | ENST00000252512.14 | NP_055839.3 | |
XPO7 | NM_001100161.2 | c.656A>G | p.Glu219Gly | missense_variant | 7/28 | NP_001093631.1 | ||
XPO7 | NM_001362802.2 | c.563A>G | p.Glu188Gly | missense_variant | 6/27 | NP_001349731.1 | ||
XPO7 | NR_156173.2 | n.738A>G | non_coding_transcript_exon_variant | 7/29 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
XPO7 | ENST00000252512.14 | c.629A>G | p.Glu210Gly | missense_variant | 7/28 | 1 | NM_015024.5 | ENSP00000252512.9 | ||
XPO7 | ENST00000518017.1 | n.824A>G | non_coding_transcript_exon_variant | 7/7 | 1 | |||||
XPO7 | ENST00000433566.8 | c.632A>G | p.Glu211Gly | missense_variant | 7/28 | 5 | ENSP00000410249.3 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 genomes
Cov.:
32
GnomAD3 exomes AF: 0.00000402 AC: 1AN: 249014Hom.: 0 AF XY: 0.00000740 AC XY: 1AN XY: 135072
GnomAD3 exomes
AF:
AC:
1
AN:
249014
Hom.:
AF XY:
AC XY:
1
AN XY:
135072
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00000479 AC: 7AN: 1461630Hom.: 0 Cov.: 29 AF XY: 0.00000550 AC XY: 4AN XY: 727092
GnomAD4 exome
AF:
AC:
7
AN:
1461630
Hom.:
Cov.:
29
AF XY:
AC XY:
4
AN XY:
727092
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome Cov.: 32
GnomAD4 genome
Cov.:
32
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Mar 08, 2024 | The c.629A>G (p.E210G) alteration is located in exon 7 (coding exon 7) of the XPO7 gene. This alteration results from a A to G substitution at nucleotide position 629, causing the glutamic acid (E) at amino acid position 210 to be replaced by a glycine (G). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Benign
T;.
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Pathogenic
D
LIST_S2
Uncertain
D;D
M_CAP
Benign
T
MetaRNN
Benign
T;T
MetaSVM
Benign
T
MutationAssessor
Uncertain
M;.
PrimateAI
Uncertain
T
PROVEAN
Uncertain
D;D
REVEL
Benign
Sift
Benign
T;T
Sift4G
Uncertain
D;D
Polyphen
B;B
Vest4
MVP
MPC
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at